Maryam Hosseini

Maryam Hosseini

Auto-generated profile, based on publicly available information

Maryam Hosseini

Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Heliyon
Verified
Journal Article
Open access
MAMohaddeseh Azadvari
Mohaddeseh Azadvari
AHAfarin Haghparast
Afarin Haghparast
ANAmin Nakhostin-Ansari
Amin Nakhostin-Ansari
SRSeyede Zahra Emami Razavi
Seyede Zahra Emami Razavi
MHMaryam Hosseini
Maryam Hosseini
Latest studies have revealed that an increasing number of Corona Virus Disease of 2019 (COVID-19) patients may continue to feel symptoms after the acute phase. This study aimed to evaluate the prevalence of musculoskeletal symptoms after the acute phase of COVID-19 and its associated factors. We designed a cross-sectional study from January 2021 to April 2021. An online questionnaire was designed and sent to patients who had recovered from COVID-19. The questionnaire contained questions on participants' demographic characteristics, COVID-19 course at its acute phase, and musculoskeletal symptoms after recovering from COVID-19. Musculoskeletal symptoms associations with patients’ characteristic and COVID-19 course was evaluated. 239 patients, including 72 (30.1%) males and 167 (69.9%) females with a mean age of 37.96 years (SD = 11.19), were included in the study. 98.74% of our patients had experienced at least one musculoskeletal symptom after recovering from COVID-19, and the most common symptom was fatigue, as 91.2% of participants experienced this symptom, followed by myalgia, headache, and low back pain. High BMI, hospitalization, and ICU admission were associated with a higher risk of musculoskeletal symptoms. This study indicated a high prevalence of persistent musculoskeletal symptoms among patients who recovered from COVID-19. Modifiable factors, such as BMI, can be targeted to reduce the prevalence of musculoskeletal symptoms in COVID-19 survivors and reduce its burden.

1 November 2020 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
TATannaz Ahadi
Tannaz Ahadi
GRGholam Reza Raissi
Gholam Reza Raissi
MHMaryam Hosseini
Maryam Hosseini
SSSimin Sajadi
Simin Sajadi
SESafoora Ebadi
Safoora Ebadi
KMKorosh Mansoori
Korosh Mansoori
Purpose of the study: Pelvic floor muscles dysfunction is one of the most important etiologies of coccydynia, therefore, manual therapies have been proposed as the first line of treatment. The purpose of this study was to investigate the effect of biofeedback as a new approach in the treatment of coccydynia. Methods: Thirty women were randomized into two groups. Both groups were injected with corticosteroid. One group received pelvic floor muscle exercises plus biofeedback while the other only performed exercises. Patient’s pain was measured using Visual Analogue Scale (VAS) in the first visit and after 1, 2 and 6 months of follow-up as well as Dallas pain and SF-36 quality of life questionnaires before and 2 months after the treatment. Results: Pain had improved significantly after 1, 2 and 6 months in both groups compared to the baseline. However, the amount of change was not different between the groups at any time interval. The results were the same for Dallas pain scale and SF-36 quality of life questionnaire. Conclusion: Adding biofeedback to pelvic floor muscle exercises did not lead to any further improvement in management of chronic coccydynia. Further studies with larger sample sizes may show the effect of biofeedback more clearly.

22 February 2025 in Journal of Kerman University of Medical Sciences
Verified
Journal Article
Open access
PDF file
MHMaryam Hosseini
Maryam Hosseini
SKSara Karimi
Sara Karimi
AHAzhdar Heydari
Azhdar Heydari
HBHamidreza Banafshe
Hamidreza Banafshe
SASamaneh Sadat Alavi
Samaneh Sadat Alavi
GHGholamali Hamidi
Gholamali Hamidi
Background: Diabetic neuropathy (DN) is known as the most troublesome of diabetes mellitus complications. There is a cross-talk between cyclooxygenase-2 (COX-2) and the enzyme NO synthase (NOS) in pain pathophysiology in the dorsal root ganglia and the spinal cord. This study aimed to determine the possible role of the NOS inhibitor, N(ω)-nitro-L-arginine methyl ester (L-NAME), or the COX-2 inhibitor, celecoxib, alone and in interaction with each other, on hyperalgesia and allodynia in rats with DN. Methods: Streptozotocin (STZ) (60 mg/kg, IP, once) was used to induce diabetes in male Wistar rats. After 72 hours, the animals were divided into groups that received celecoxib (5 mg/kg), L-arginine (L-ARG) (50 mg/kg), or L-NAME (50 mg/kg) alone and two groups that received a combination of celecoxib with either L-ARG or L-NAME. The von Frey and acetone tests were used to evaluate hyperalgesia and allodynia 14 days after treatment. Results: A significant increase in the withdrawal threshold level was observed in the groups receiving celecoxib alone (P<0.001) and in combination with L-ARG (P<0.001) or L-NAME (P<0.001). The reaction percentage in the acetone test significantly decreased in the celecoxib, L-NAME, celecoxib+L-ARG, and celecoxib+L-NAME groups (P<0.001) compared with the diabetic control group. Conclusion: The main finding was that inhibiting COX-2 and NOS reduced hyperalgesia and mechanical allodynia in diabetic rats. Also, the results revealed that there is cross-talk between these two enzymes.